Novel peptide therapeutics for treatment of infections.

As antibiotic resistance increases worldwide, there is an increasing pressure to develop novel classes of antimicrobial compounds to fight infectious disease. Peptide therapeutics represent a novel class of therapeutic agents. Some, such as cationic antimicrobial peptides and peptidoglycan recognition proteins, have been identified from studies of innate immune effector mechanisms, while others are completely novel compounds generated in biological systems. Currently, only selected cationic antimicrobial peptides have been licensed, and only for topical applications. However, research using new approaches to identify novel antimicrobial peptide therapeutics, and new approaches to delivery and improving stability, will result in an increased range of peptide therapeutics available in the clinic for broader applications.

[1]  P. Mellroth,et al.  A Scavenger Function for a DrosophilaPeptidoglycan Recognition Protein* , 2003, The Journal of Biological Chemistry.

[2]  Xia Li,et al.  APD2: the updated antimicrobial peptide database and its application in peptide design , 2008, Nucleic Acids Res..

[3]  T. Trautner,et al.  Methylation of DNA in prokaryotes. , 1993, EXS.

[4]  M. Ghadiri,et al.  Systemic Antibacterial Activity of Novel Synthetic Cyclic Peptides , 2005, Antimicrobial Agents and Chemotherapy.

[5]  André Pèlegrin,et al.  Cell-penetrating and cell-targeting peptides in drug delivery. , 2008, Biochimica et biophysica acta.

[6]  M. Ghadiri,et al.  Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. , 2001, Nature.

[7]  R. Guan,et al.  Crystal structure of human peptidoglycan recognition protein Iα bound to a muramyl pentapeptide from Gram‐positive bacteria , 2006 .

[8]  H. Steiner,et al.  A mammalian peptidoglycan recognition protein with N-acetylmuramoyl-L-alanine amidase activity. , 2003, Biochemical and biophysical research communications.

[9]  Jun Wang,et al.  Protein and small molecule microarrays: powerful tools for high-throughput proteomics. , 2006, Molecular bioSystems.

[10]  R. Guan,et al.  Crystal structure of human peptidoglycan recognition protein I alpha bound to a muramyl pentapeptide from Gram-positive bacteria. , 2006, Protein science : a publication of the Protein Society.

[11]  James M. Wilson,et al.  Human β-Defensin-1 Is a Salt-Sensitive Antibiotic in Lung That Is Inactivated in Cystic Fibrosis , 1997, Cell.

[12]  D. Payan,et al.  A novel artificial loop scaffold for the noncovalent constraint of peptides. , 2000, Chemistry & biology.

[13]  Pasi Soininen,et al.  Activity and stability of human kallikrein‐2‐specific linear and cyclic peptide inhibitors , 2007, Journal of peptide science : an official publication of the European Peptide Society.

[14]  V. Robinson,et al.  A dam mutant of Yersinia pestis is attenuated and induces protection against plague. , 2005, FEMS microbiology letters.

[15]  D. Low,et al.  DNA Adenine Methylase Is Essential for Viability and Plays a Role in the Pathogenesis of Yersinia pseudotuberculosis andVibrio cholerae , 2001, Infection and Immunity.

[16]  Erik De Clercq,et al.  Emerging anti-HIV drugs. , 2005 .

[17]  S. Benkovic,et al.  A systematic method for identifying small-molecule modulators of protein-protein interactions. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Irache,et al.  Mannose-targeted systems for the delivery of therapeutics , 2008, Expert opinion on drug delivery.

[19]  R. Allaker.  Host defence peptides-a bridge between the innate and adaptive immune responses. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[20]  R. Dziarski,et al.  Peptidoglycan Recognition Proteins , 2001, The Journal of Biological Chemistry.

[21]  T. Webb,et al.  Current directions in the evolution of compound libraries. , 2005, Current opinion in drug discovery & development.

[22]  E. Tate,et al.  Chemical and biomimetic total syntheses of natural and engineered MCoTI cyclotides. , 2008, Organic & biomolecular chemistry.

[23]  Oreola Donini,et al.  An anti-infective peptide that selectively modulates the innate immune response , 2007, Nature Biotechnology.

[24]  R. Wattiez,et al.  Characterization of human serum N-acetylmuramyl-L-alanine amidase purified by affinity chromatography. , 1995, Protein Expression and Purification.

[25]  D. Wolf,et al.  Proteasomes: destruction as a programme. , 1996, Trends in biochemical sciences.

[26]  D. Low,et al.  An essential role for DNA adenine methylation in bacterial virulence. , 1999, Science.

[27]  C. Ross,et al.  Gene Silencing and Overexpression of Porcine Peptidoglycan Recognition Protein Long Isoforms: Involvement in β-Defensin-1 Expression , 2005, Infection and Immunity.

[28]  J. Carulli,et al.  Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the epidermal differentiation complex and are candidate genes for the Psors4 locus on chromosome 1q21 , 2006, Human Genetics.

[29]  S. Benkovic,et al.  Production of cyclic peptides and proteins in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Vaara,et al.  Agents that increase the permeability of the outer membrane. , 1992, Microbiological reviews.

[31]  G. Pirri,et al.  Antimicrobial peptides: an overview of a promising class of therapeutics , 2007, Central European Journal of Biology.

[32]  K. S. Kumar,et al.  Peptide‐polymer biotherapeutic synthesis on novel cross‐linked beads with “spatially tunable” and “isolated” functional sites , 2008, Biopolymers.

[33]  Ronald W. Barrett,et al.  Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin , 1996, Science.

[34]  S. Billstein.  How the pharmaceutical industry brings an antibiotic drug to market in the United States , 1994, Antimicrobial Agents and Chemotherapy.

[35]  John J Irwin,et al.  How good is your screening library? , 2006, Current opinion in chemical biology.

[36]  Jan Reichert,et al.  The IMB Jena Image Library of Biological Macromolecules: 2002 update , 2002, Nucleic Acids Res..

[37]  H. Ulrich,et al.  DNA and RNA aptamers: from tools for basic research towards therapeutic applications. , 2006, Combinatorial chemistry & high throughput screening.

[38]  R. Hancock,et al.  Cationic peptides: effectors in innate immunity and novel antimicrobials. , 2001, The Lancet. Infectious diseases.

[39]  T. Baker,et al.  A specificity-enhancing factor for the ClpXP degradation machine. , 2000, Science.

[40]  Stephen J Benkovic,et al.  Split-intein mediated circular ligation used in the synthesis of cyclic peptide libraries in E. coli , 2007, Nature Protocols.

[41]  W. Goldman,et al.  Dual strategies for peptidoglycan discrimination by peptidoglycan recognition proteins (PGRPs). , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Ptak,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent , 2008, Antimicrobial Agents and Chemotherapy.

[43]  N. Fukuishi,et al.  Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity. , 2008, Biological & pharmaceutical bulletin.

[44]  Reynier Báez,et al.  PEGylated Interferon-α2b: A Branched 40K Polyethylene Glycol Derivative , 2005, Pharmaceutical Research.

[45]  N. Udupa,et al.  Pharmacokinetic study of niosome encapsulated insulin. , 2000, Indian journal of experimental biology.

[46]  Roger Brent,et al.  Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2 , 1996, Nature.

[47]  Juan R. Granja,et al.  Antibacterial agents based on the cyclic d,l-α-peptide architecture , 2001, Nature.

[48]  Jeremy Luban,et al.  Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B , 1993, Cell.

[49]  R. Dziarski,et al.  Defect in neutrophil killing and increased susceptibility to infection with nonpathogenic gram-positive bacteria in peptidoglycan recognition protein-S (PGRP-S)-deficient mice. , 2003, Blood.

[50]  Jürgen Sühnel,et al.  A comparative view at comprehensive information resources on three-dimensional structures of biological macro-molecules. , 2007, Briefings in functional genomics & proteomics.

[51]  M. Zasloff,et al.  Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Hancock,et al.  Antibacterial peptides for therapeutic use: obstacles and realistic outlook. , 2006, Current opinion in pharmacology.

[53]  R. Guan,et al.  Crystal Structure of the C-terminal Peptidoglycan-binding Domain of Human Peptidoglycan Recognition Protein Iα* , 2004, Journal of Biological Chemistry.

[54]  R Wenger,et al.  Cyclosporine and analogues: structural requirements for immunosuppressive activity. , 1985, Transplantation proceedings.

[55]  D. Davidson,et al.  Impact of LL‐37 on anti‐infective immunity , 2005, Journal of leukocyte biology.

[56]  Jan Reichert,et al.  The IMB Jena Image Library of Biological Macromolecules - New Features , 2001, German Conference on Bioinformatics.

[57]  M. Ashida,et al.  Purification of a Peptidoglycan Recognition Protein from Hemolymph of the Silkworm, Bombyx mori* , 1996, The Journal of Biological Chemistry.

[58]  A. Pini,et al.  Bioactive peptides from libraries. , 2005, Chemistry & biology.

[59]  R. Dziarski,et al.  Peptidoglycan recognition proteins: pleiotropic sensors and effectors of antimicrobial defences , 2007, Nature Reviews Microbiology.

[60]  K. Taira,et al.  Screening and determination of gene function using randomized ribozyme and siRNA libraries. , 2006, Handbook of experimental pharmacology.

[61]  Q. Wang,et al.  Selective Recognition of Synthetic Lysine and meso-Diaminopimelic Acid-type Peptidoglycan Fragments by Human Peptidoglycan Recognition Proteins Iα and S* , 2005, Journal of Biological Chemistry.

[62]  Reynier Báez,et al.  PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. , 2005, Pharmaceutical research.

[63]  R. Sauer,et al.  Role of a Peptide Tagging System in Degradation of Proteins Synthesized from Damaged Messenger RNA , 1996, Science.

[64]  R. Dziarski,et al.  Human Peptidoglycan Recognition Proteins Require Zinc to Kill Both Gram-Positive and Gram-Negative Bacteria and Are Synergistic with Antibacterial Peptides1 , 2007, The Journal of Immunology.

[65]  B. Wolff,et al.  Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication , 1995, Journal of virology.

[66]  A. Schmidtchen,et al.  Evaluation of Strategies for Improving Proteolytic Resistance of Antimicrobial Peptides by Using Variants of EFK17, an Internal Segment of LL-37 , 2008, Antimicrobial Agents and Chemotherapy.

[67]  E V Koonin,et al.  AAA+: A class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes. , 1999, Genome research.

[68]  M. Grace,et al.  Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-α Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway* , 2005, Journal of Biological Chemistry.

[69]  Y. Shai,et al.  Cyclization of a cytolytic amphipathic alpha-helical peptide and its diastereomer: effect on structure, interaction with model membranes, and biological function. , 2000, Biochemistry.

[70]  R. Guan,et al.  Crystal structure of human peptidoglycan recognition protein S (PGRP-S) at 1.70 A resolution. , 2005, Journal of molecular biology.

[71]  K. Brogden.  Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? , 2005, Nature Reviews Microbiology.

[72]  Bryan J. Venters,et al.  Discovery of antibacterial cyclic peptides that inhibit the ClpXP protease , 2007, Protein science : a publication of the Protein Society.

[73]  K. Fukase,et al.  Human peptidoglycan recognition protein S is an effector of neutrophil-mediated innate immunity. , 2005, Blood.

[74]  J. Fiddes,et al.  Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity , 1997, Antimicrobial agents and chemotherapy.

[75]  M. Schreier,et al.  Molecular Mechanisms of Immunosuppression by Cyclosporins , 1993, Annals of the New York Academy of Sciences.

[76]  Stephen J Benkovic,et al.  Genetic Selection of Cyclic Peptide Dam Methyltransferase Inhibitors , 2008, Chembiochem : a European journal of chemical biology.

[77]  R. Hancock,et al.  Peptide Antimicrobial Agents , 2006, Clinical Microbiology Reviews.

[78]  C. Papageorgiou,et al.  Calcineurin has a very tight-binding pocket for the side chain of residue 4 of cyclosporin , 1994 .

[79]  L. Phillips,et al.  The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults. , 2002, The Journal of clinical endocrinology and metabolism.

[80]  Robert T Sauer,et al.  Ribosome rescue: tmRNA tagging activity and capacity in Escherichia coli , 2005, Molecular microbiology.

[81]  P. Shaw,et al.  Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. , 1999, Life sciences.

[82]  P. Schatz,et al.  Chronic Pharmacological and Safety Evaluation of Hematide™, a PEGylated Peptidic Erythropoiesis-Stimulating Agent, in Rodents , 2009, Basic & clinical pharmacology & toxicology.

[83]  R. Titball,et al.  Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague. , 2005, Microbiology.

[84]  H. Steiner,et al.  A peptidoglycan recognition protein in innate immunity conserved from insects to humans. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[85]  A. Samad,et al.  Liposomal drug delivery systems: an update review. , 2007, Current drug delivery.

[86]  Jeremy Luban,et al.  Target Cell Cyclophilin A Modulates Human Immunodeficiency Virus Type 1 Infectivity , 2004, Journal of Virology.

[87]  D. Coomber,et al.  CIS display: In vitro selection of peptides from libraries of protein-DNA complexes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Koichi Fukase,et al.  Human Peptidoglycan Recognition Protein-L Is an N-Acetylmuramoyl-L-alanine Amidase* , 2003, Journal of Biological Chemistry.

[89]  R. Dziarski,et al.  Peptidoglycan Recognition Proteins Are a New Class of Human Bactericidal Proteins* , 2006, Journal of Biological Chemistry.

[90]  G. Domagk.  Eine neue Klasse von Desinfektionsmitteln , 1935 .

[91]  Rongjin Guan,et al.  Structural basis for peptidoglycan binding by peptidoglycan recognition proteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[92]  H. Alpár,et al.  Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine. , 2006, Vaccine.

[93]  K. Lee,et al.  Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. , 1999, Biochemical pharmacology.

[94]  M. Zaiou.  Multifunctional antimicrobial peptides: therapeutic targets in several human diseases , 2007, Journal of Molecular Medicine.

[95]  D. Hultmark,et al.  Sequence and specificity of two antibacterial proteins involved in insect immunity , 1981, Nature.

[96]  Sérgio Simões,et al.  On the formulation of pH-sensitive liposomes with long circulation times. , 2004, Advanced drug delivery reviews.

[97]  Derek S. Tan,et al.  Diversity-oriented synthesis: exploring the intersections between chemistry and biology , 2005, Nature chemical biology.

[98]  R. Crabbé,et al.  The cyclophilin inhibitor Debio‐025 shows potent anti–hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus , 2008, Hepatology.

[99]  D. Hultmark,et al.  A family of peptidoglycan recognition proteins in the fruit fly Drosophila melanogaster. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[100]  L. van der Fits,et al.  Identification of serum N-acetylmuramoyl-l-alanine amidase as liver peptidoglycan recognition protein 2. , 2005, Biochimica et biophysica acta.

[101]  J. Tomás,et al.  Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. , 2008, Microbiology.

[102]  Laxmi R Fogueri,et al.  Smart polymers for controlled delivery of proteins and peptides: a review of patents. , 2009, Recent patents on drug delivery & formulation.

[103]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[104]  L. Baillie,et al.  Mucosal or Parenteral Administration of Microsphere-Associated Bacillus anthracis Protective Antigen Protects against Anthrax Infection in Mice , 2002, Infection and Immunity.

[105]  A. Harris,et al.  Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. , 1994, Gut.

[106]  F. Wirsching,et al.  Directed evolution towards protease-resistant hirudin variants. , 2003, Molecular genetics and metabolism.

[107]  G. Pier,et al.  ClpXP proteases positively regulate alginate overexpression and mucoid conversion in Pseudomonas aeruginosa. , 2008, Microbiology.

[108]  A. Chinnaiyan,et al.  Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95 , 1996, Science.

[109]  A. Goldberg,et al.  New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. , 1997, Biological chemistry.

[110]  H. Cai,et al.  The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis. , 2008, DNA and cell biology.

[111]  R. Hancock.  Alterations in outer membrane permeability. , 1984, Annual review of microbiology.

[112]  D. Pérez-Caballero,et al.  Cyclophilin Interactions with Incoming Human Immunodeficiency Virus Type 1 Capsids with Opposing Effects on Infectivity in Human Cells , 2005, Journal of Virology.

[113]  N. Wright,et al.  Maintenance of normal intestinal mucosa: function, structure, and adaptation. , 1994, Gut.